A Phase I Dose Escalation And Expansion Study Of The Next Generation Oral Serd Azd9833 In Women With Er-Positive, Her2-Negative Advanced Breast Cancer.

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 24|浏览40

暂无评分

摘要

1024Background: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader (SERD) that has shown antitumor efficacy in a range of preclinical models of breast cancer. Methods: SERE...

查看译文

关键词

oral serd azd9833,advanced breast cancer,breast cancer,er-positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要